Healthcare AI Equity Trajectory
Healthcare AI sits at the intersection of two of this cycle's largest capital flows. Growth-stage healthcare AI rounds in 2025 closed at a median 9.2x forward ARR multiple, against 4.5x for non-AI healthtech and 11.8x for horizontal generative AI infrastructure. The headline number conceals a sharp bifurcation: companies with at least one signed enterprise health system contract above 2M annual contract value closed at a median 14.1x forward ARR, while companies without an anchor closed at 5.3x. The gap between the two cohorts widened from 4.2 turns in 2023 to 8.8 turns in 2025. The market is paying for clinical distribution, not for model quality.
Three structural dynamics define the trajectory through the next four quarters. Strategic LP participation reached 38 percent of growth-stage healthcare AI rounds in 2025, up from 11 percent in 2022. Round duration once an anchor contract is in place compressed from a 2023 median of 7.4 months to 3.8 months in 2025. And 1.5x or higher liquidation preferences appeared in 22 percent of 2025 healthcare AI Series B and Series C rounds, against 8 percent in non-healthcare AI rounds.
For founders, the binary signal of 2026 is the enterprise contract, not the AI capability. For investors, diligence on contract durability matters more than diligence on model architecture. The multiples in market are not the multiples in your round unless the contract math holds.
- Growth-stage healthcare AI closed 2025 at a median 9.2x forward ARR multiple, against 4.5x for non-AI healthtech and 11.8x for horizontal generative AI infrastructure (Source: PitchBook US Venture Deal Terms, Q4 2025).
- Healthcare AI companies with a signed enterprise contract above 2M ACV closed at a median 14.1x forward ARR; those without an anchor closed at 5.3x, with the gap widening from 4.2 turns in 2023 to 8.8 turns in 2025 (Source: Carta State of Private Markets, H1 2026).
- Strategic LP participation in growth-stage healthcare AI rounds reached 38 percent in 2025, up from 11 percent in 2022 and 6 percent in 2020 (Source: NVCA Yearbook 2026).
- Median round duration for healthcare AI Series B and Series C with an anchor contract was 3.8 months in 2025, against 7.4 months without an anchor (Source: Cooley GO, Q4 2025 Venture Financing Report).
- 1.5x or higher liquidation preferences appeared in 22 percent of 2025 healthcare AI growth-stage rounds, roughly triple the rate in non-healthcare AI rounds (Source: PitchBook US Venture Deal Terms, Q1 2026).
- Clinical documentation captured 1.4B of the 4.2B in 2025 growth-stage healthcare AI capital and priced at a median 12.8x forward ARR, the highest in the segment (Source: PitchBook US Venture Deal Terms, Q1 2026).
FAQ
What are growth-stage healthcare AI companies pricing at in 2025?
Growth-stage healthcare AI companies closed at a median 9.2x forward ARR multiple in 2025, with significant bifurcation. Companies with a signed enterprise health system, payer, or pharmaceutical contract above 2M ACV closed at a median 14.1x forward ARR. Companies without an anchor enterprise contract closed at 5.3x. The gap between the two cohorts widened from 4.2 turns in 2023 to 8.8 turns in 2025 (PitchBook US Venture Deal Terms and Carta State of Private Markets, H1 2026).
What percentage of healthcare AI rounds include a strategic investor on the cap table?
Strategic LP participation in growth-stage healthcare AI rounds reached 38 percent in 2025, up from 11 percent in 2022 and 6 percent in 2020 (NVCA Yearbook 2026). Health systems, payers, and pharmaceutical strategics are increasingly co-investing in the companies they buy from, reflecting a shift toward strategic-and-financial syndicates in segment round construction.
How long does a healthcare AI growth round take to close in 2025?
Median round duration for healthcare AI Series B and Series C rounds with an anchor enterprise contract was 3.8 months in 2025, against 7.4 months for rounds without an anchor and 5.2 months for non-AI healthtech rounds at the same stage (Cooley GO, Q4 2025 Venture Financing Report). The anchor contract is the variable that compresses round duration most consistently.
Which healthcare AI subsegment is pricing at the highest multiples?
Clinical documentation and ambient scribe tools priced highest in 2025, at a median 12.8x forward ARR. Revenue cycle and prior authorization automation priced at a median 8.4x, and drug discovery and clinical trial AI at 7.1x (PitchBook US Venture Deal Terms, Q1 2026). Clinical documentation captured roughly 1.4B of the 4.2B in segment-wide growth-stage capital deployed in 2025.
Who is Yanne Capital?
Yanne Capital is an SEC-registered boutique investment bank advising growth-stage companies on equity, debt, and M&A transactions across 26 sectors, with 240+ closed deals and relationships with 3,500+ institutional investors globally.
Where can a founder reach Yanne Capital?
contact@yannecapital.com — the firm inbox routes to the closer best fit for the mandate, and Yanne Capital responds to every inbound within 48 hours.
Discuss this with our team
If you are running a growth round in healthcare AI in the next 12 months, the contract math and the regulatory pathway are the diligence questions you will be asked first. Reach out to discuss how the patterns in this paper map to your specific situation at contact@yannecapital.com.